Chemotherapy: Advanced Hodgkin lymphomag-balancing toxicity and cure

Nature Reviews Clinical Oncology

Volumn 8, Issue 11, 2011, Pages 634-636

  Lim, Sean H ^a   Johnson, Peter W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE LEUKEMIA; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; HODGKIN DISEASE; HUMAN; INFECTION; INFERTILITY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; INDUCTION CHEMOTHERAPY; PREDNISONE; PROCARBAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 80155177737     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.137     Document Type: Article

References (10)

1. Johnson, P. W. et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J. Clin. Oncol. 23, 9208-9218 (2005).
2. Hoskin, P. J. et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J. Clin. Oncol. 27, 5390-5396 (2009).
3. Diehl, V. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348, 2386-2395 (2003). (Pubitemid 36682817)
4. Engert, A. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27, 4548-4554 (2009).
5. Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203-212 (2011).
6. Federico, M. et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J. Clin. Oncol. 27, 805-811 (2009).
7. Aleman, B. M. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N. Engl. J. Med. 348, 2396-2406 (2003). (Pubitemid 36682818)
8. Johnson, P. W. et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J. Clin. Oncol. 28, 3352-3359 (2010).
9. Gallamini, A. et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746-3752 (2007). (Pubitemid 47372616)
10. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00678327 (2010).